Toward depression remission: balancing efficacy and tolerability.
Emerging research has found that different neurotransmitters play roles in the regulation of depressive symptomatology and adverse events associated with antidepressant treatment. Residual depressive symptoms and adverse events can lead to noncompliance and the discontinuation of treatment. Several approaches may help clinicians address residual symptoms and tolerability issues in patients with depression.
Montejo
Angel L
AL
University Hospital of Salamanca, Salamanca, Spain.
D000928:Antidepressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D010349:Patient Compliance; D016896:Treatment Outcome
D000928:Antidepressive Agents